PVG Asset Management Corp Makes New $161,000 Investment in BioAtla, Inc. (NASDAQ:BCAB)

PVG Asset Management Corp purchased a new position in BioAtla, Inc. (NASDAQ:BCAB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 65,335 shares of the company’s stock, valued at approximately $161,000. BioAtla makes up about 0.8% of PVG Asset Management Corp’s portfolio, making the stock its 28th biggest holding. PVG Asset Management Corp owned approximately 0.14% of BioAtla at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of BCAB. Pale Fire Capital SE grew its position in BioAtla by 204.6% in the fourth quarter. Pale Fire Capital SE now owns 48,383 shares of the company’s stock worth $119,000 after acquiring an additional 32,500 shares during the period. Perceptive Advisors LLC purchased a new position in shares of BioAtla in the 4th quarter valued at about $180,000. Panagora Asset Management Inc. boosted its holdings in BioAtla by 110.0% in the fourth quarter. Panagora Asset Management Inc. now owns 111,366 shares of the company’s stock valued at $274,000 after purchasing an additional 58,336 shares in the last quarter. Finally, Sectoral Asset Management Inc. increased its stake in BioAtla by 26.9% in the third quarter. Sectoral Asset Management Inc. now owns 706,062 shares of the company’s stock valued at $1,200,000 after purchasing an additional 149,544 shares during the last quarter. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

BioAtla Stock Performance

NASDAQ:BCAB traded down $0.04 during midday trading on Monday, reaching $1.56. The stock had a trading volume of 95,295 shares, compared to its average volume of 604,306. The firm has a fifty day simple moving average of $2.40 and a two-hundred day simple moving average of $2.42. BioAtla, Inc. has a 12-month low of $1.24 and a 12-month high of $4.02.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09. On average, sell-side analysts expect that BioAtla, Inc. will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

BCAB has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of BioAtla in a report on Wednesday, May 15th. JMP Securities dropped their price objective on BioAtla from $12.00 to $5.00 and set a “market outperform” rating on the stock in a report on Thursday, May 23rd.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.